The triplet gemcitabine (G), epirubicin (E) and docetaxel (Doc) is feasible, safe and highly active as primary systemic therapy (PST) of patients (pts) with multicentric phase I/II trial

✍ Scribed by A. Schneeweiss; M. Geberth; K. Krauss; F. Beldermann; U. Wagner; D. von Fournier; R. Hamerla; D. Wallweiner; G. Bastert; J. Huober

• Book ID: 114315639
• Publisher: Elsevier Science
• Year: 2003
• Tongue: English
• Weight: 192 KB
• Volume: 12
• Category: Article
• ISSN: 0960-9776
• DOI: 10.1016/s0960-9776(03)80114-5